Keyphrases
Acute Lymphoblastic Leukemia
74%
BCP-ALL
65%
Minimal Residual Disease
41%
Pediatric
34%
IKZF1
29%
IKZF1 Deletion
25%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
24%
ETV6-RUNX1
21%
Event-free Survival
20%
Childhood Acute Lymphoblastic Leukemia
20%
Hyperdiploid
19%
Leukemia Patients
17%
Pediatric Patients
16%
PAX5
14%
Intrachromosomal Amplification of Chromosome 21 (iAMP21)
13%
Poor Outcome
13%
Overall Survival
12%
Leukemia
12%
Relapsed or Refractory
12%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
12%
Tyrosine Kinase Inhibitor
11%
High Risk
11%
Pediatric Acute Lymphoblastic Leukemia
10%
Improved Outcomes
10%
BCR-ABL1
10%
Down Syndrome
10%
Media Risk
10%
Copy number
10%
Targeted Therapy
10%
Acute Lymphoblastic Leukemia Cells
10%
Copy number Variation
10%
Genetic Subtypes
10%
B-cell Precursors
10%
Confidence Interval
9%
Cell Tumor
9%
Relapse Risk
9%
Gemtuzumab Ozogamicin
9%
Prognostic Effect
9%
Tyrosine Kinase Inhibitor Resistance
9%
Kinase Domain mutations
9%
3D Live Imaging
9%
Engineered T Cells
9%
Ara-C
9%
Imaging Platform
9%
Common Region
9%
Central Nervous System Involvement
9%
IKZF1 Gene Deletion
9%
Cell Behavior
9%
AUTS2
9%
Cytarabine
9%
Tumor Response
9%
Transcriptional Landscape
9%
Behavioral Response
9%
Mutational Landscape
9%
Antibody-dependent Cellular Phagocytosis
9%
Chromosome 21
9%
Childhood B-ALL
9%
Cyclin C
9%
Lymphoblastic Lymphoma
9%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
8%
Aberrations
8%
Hematopoietic Stem Cell Transplantation
8%
Leukemic Cells
7%
Dutch
7%
RNA Sequencing (RNA-seq)
7%
Newly Diagnosed
7%
Signal Transduction Inhibitors
7%
CD22
6%
Dose-limiting Toxicity
6%
Tumor
6%
Prednisone
6%
Whole Exome Sequencing
6%
Standard Risk
6%
Treatment Protocol
6%
Bone Marrow
6%
Clinical Trials
6%
Risk Stratification
6%
Pediatric Cancer
5%
Working Diagnosis
5%
Clinical Outcomes
5%
Therapeutic Target
5%
Blood Cancer
5%
DUX4
5%
Lymphoblastic Malignancies
5%
Extramedullary
5%
B Cell Development
5%
Phase II Trial
5%
Overall Response Rate
5%
Primary B Cells
5%
T Cells
5%
Mesenchymal Stromal Cells
5%
Drug Resistance
5%
Fusion Gene
5%
Immune Cells
5%
Risk Score
5%
ABL1
5%
TCF3-PBX1
5%
Bosutinib
5%
Survival Rate
5%
Chromosomal Instability
5%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Precursor
86%
IKZF1
40%
Chromosome 21
23%
RUNX1
22%
ETV6
22%
Down Syndrome
17%
RNA Sequence
16%
High Risk Population
16%
Event Free Survival
14%
Genetics
14%
Tyrosine Kinase Inhibitor
13%
Kinase
13%
Phosphotransferase
13%
PAX5
13%
Overall Survival
13%
T Cell
10%
Germline
9%
Germ Cell
9%
Cell Function
9%
Gene Deletion
9%
Cytarabine
9%
SH3 Domain
9%
Clinical Trial
8%
Coculture
8%
Immunocompetent Cell
7%
Adolescence
6%
Cytogenetics
6%
Prednisone
6%
Exome Sequencing
6%
Imatinib
5%
Targeted Therapy
5%
DUX4
5%
Enhancer Region
5%
Intravenous Immunoglobulin
5%
Cell Maturation
5%
Chromosome Instability
5%
Janus Kinase
5%
Cell Viability
5%
Drug Resistance
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
96%
B Cell
40%
Precursor
34%
Minimal Residual Disease
33%
Pediatrics
31%
Acute B-Cell Lymphoblastic Leukemia
12%
Pediatrics Patient
11%
Neoplasm
11%
Malignant Neoplasm
9%
Leukemia in Children
9%
Overall Survival
9%
Inotuzumab Ozogamicin
9%
Tyrosine-Kinase Inhibitor
9%
Cyclin C
9%
Risk Stratification
9%
Event Free Survival
9%
Leukemia
8%
Germ Cell
8%
Hematopoietic Stem Cell Transplantation
7%
Leukemia Cell
7%
Personalized Medicine
7%
Acute Lymphocytic Leukemia
6%
Cancer
6%
Adolescence
6%
Prognostic Factor
5%
High Risk Population
5%
Clinical Trial
5%
Hematological Cancer
5%
Janus Kinase
5%